Search clinical trials for: Zytiga

Total 201 results

Organon and Co

Completed

Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)

Hypercholesterolemia
Ivan de Kouchkovsky, MD

Not yet recruiting

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) MRI as a Response Monitoring Tool to Neoadjuvant Abiraterone

Prostate Cancer | High Risk Prostate Carcinoma

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, New Zealand
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

Hyperlipidemia

United States, Denmark, Taiwan, Korea, Republic of, Australia, Belgium, Canada, South Africa, France, Turkey
Organon and Co
Merck Sharp & Dohme LLC

Completed

Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)

Atherosclerosis | Hypercholesterolemia
University of Oxford
National Health and Medical Research Council, Australia; Merck Sharp & Dohme... and other collaborators

Completed

Study of Heart and Renal Protection (SHARP)

Kidney Disease, Chronic

United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants

Healthy

Belgium
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Dyslipidemias | Dyslipidaemias

United States
Organon and Co

Completed

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)

Hyperlipidemia
Organon and Co

Completed

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

Hypercholesterolemia
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

Hypercholesterolemia
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

Hypercholesterolemia
Organon and Co
Merck Sharp & Dohme LLC

Terminated

Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)

Coronary Artery Disease | Atherosclerosis | Hypercholesterolemia
NYU Langone Health

Completed

CHOlesterol Lowering and Residual Risk in Type 2 Diabetes (CHORD)

Type 2 Diabetes

United States
Organon and Co

Completed

Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)

Hypercholesterolemia
Organon and Co

Completed

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Hypercholesterolemia
Mamta Parikh
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma

United States
Fudan University

Recruiting

Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer

Prostate Cancer

China
Karolinska Institutet
The Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaborators

Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sweden, Belgium, Switzerland, Norway
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Hypercholesterolemia

United States
Organon and Co
Schering-Plough

Completed

MD Ezetimibe Cyclosporine Interaction (0653-057)

Cholesterol
Esperion Therapeutics, Inc.

Completed

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Diabetes Mellitus, Type 2 | Diabetes | Cholesterolemia

United States
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Hyperlipidemia

Canada, Denmark, France, United States, Czechia, New Zealand, Australia, South Africa, Italy, United Kingdom, Netherlands, Germany, Norway
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Carcinoma Metastatic in the Bone

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
Medical Research Council

Active, not recruiting

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

Prostate Cancer

United Kingdom, Switzerland
Organon and Co

Completed

A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)

Hypercholesterolemia
Abbott

Completed

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Dyslipidemias | Coronary Heart Disease | Mixed Dyslipidemia | Combined (Atherogenic) Dyslipidemia

United States
Amgen

Completed

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Hyperlipidemia

United States, Denmark, France, Italy, Czechia, Taiwan, Switzerland, Korea, Republic of, Germany, Hong Kong, Netherlands, Australia, Belgium, Canada, Hungary, South Africa, Russian Federation, Spain, United Kingdom, Sweden, Mexico
University of Washington
National Cancer Institute (NCI)

Terminated

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma | Castration-Sensitive Prostate Carcinoma

United States
M.D. Anderson Cancer Center
AstraZeneca

Recruiting

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Bladder Cancer | Urothelial Carcinoma

United States
National Cancer Institute (NCI)

Completed

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
Jonsson Comprehensive Cancer Center
Janssen Inc.

Active, not recruiting

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Recurrent Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation

United States
University College, London
Novartis; Cancer Research UK; Janssen Pharmaceutica NV

Not yet recruiting

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)

Prostate Cancer Metastatic
University of Washington
Blue Earth Diagnostics

Recruiting

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Prostate Adenocarcinoma

United States
University of Washington
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Completed

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7

United States
NYU Langone Health
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Cholesterol Lowering and Residual Risk in Diabetes, Type 1 (CHORD1)

Type 1 Diabetes

United States
GlaxoSmithKline

Completed

Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Epilepsy
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Metastatic Castration-Resistant Prostate Cancer

United States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma in the Soft Tissue | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States, Puerto Rico
M.D. Anderson Cancer Center

Completed

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
University of Utah

Terminated

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC)

Stage IV Prostate Cancer | Metastatic Prostatic Adenocarcinoma | Castration-Sensitive Prostate Carcinoma | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone

United States
M.D. Anderson Cancer Center

Recruiting

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Castration-Sensitive Prostate Carcinoma

United States
OHSU Knight Cancer Institute
Janssen Scientific Affairs, LLC; Oregon Health and Science University

Active, not recruiting

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration-Sensitive Prostate Carcinoma

United States
Baylor College of Medicine
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Peripheral Arterial Disease

United States
Mayo Clinic

Recruiting

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer

Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States

Search clinical trials for: Zytiga

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations